Bristol-Myers deal to acquire Juno parent Celgene delayed amid FTC concerns by James Thorne on June 24, 2019June 24, 2019 at 10:57 am The $74 billion merger of Bristol-Myers Squibb and Celgene has been delayed as FTC pushback spurred Celgene to divest a major psoriasis drug. The news rattled investors’ confidence and sent… Read More